Skip to main content UK The UK's free public sector contract intelligence platform. 160,000+ live opportunities from every official UK procurement portal.
PA23 Ready UK Data Daily Updates
BidWriter Found a contract? BidWriter drafts, scores and manages the bid — AI bid writing from your own evidence.
eSourcing OS For buyers. The platform contracting authorities run their tenders, frameworks and DPS on.
See eSourcing OS → 🇺🇸 WinAContract InternationalBidding on US federal & state contracts? Use our American platform:
© 2026 eSourcing Data Ltd · Company No. 16391108 Registered in England & Wales
Data sourced under Crown Copyright from official UK government portals 🇬🇧
Loading contract search results…
Loading contract details…
#2c3e50#3aaee0
Awarded: NHS National Generic Pharmaceuticals Wave 13 | Pfizer Ltd | WinAContract
NHS National Generic Pharmaceuticals Wave 13 Private Sector Award notice Closed SME-friendly
Source: Contracts Finder Notice Type: Award notice Buyer: ATAMIS LTD Main Category: Goods Procurement Method: Open procedure (below threshold) Tender Status: Closed Estimated Value (ex. VAT):
Award outcome Awarded to (99 suppliers)
Pfizer Ltd GB-CFS-183738
Merck Sharpe & Dohme (UK) Limited GB-CFS-183732
Allergan GB-CFS-183741
Medreich PLC GB-CFS-215186
ennogen healthcare ltd GB-CFS-209845
GlaxoSmithKline UK Limited GB-CFS-198842
Syri Limited (T/A Thame Laboratories) GB-CFS-215187
hameln pharma ltd GB-CFS-215188
medac Pharma LLP GB-CFS-186546
Description Invitation to offer for NHS National Generic Pharmaceuticals Wave 13
Offer reference number: CM/PHG/17/5532
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
Transition (Everolimus)
CESW: 1 March 2022 - 30 September 2023 (19 months)
LSNE: 1 March 2022 - 31 January 2023 (11 months)
NWLN: 1 March 2022 - 31 January 2023 (11 months)
Oral Products plus non-parenterals
All Regions: 1 March 2022 - 31 May 2024 (27 months)
Hospital Only Products
CESW: 1 February 2022 - 30 September 2023 (20 months)
LSNE: 1 February 2022 - 31 May 2024 (28 months)
NWLN: 1 February 2022 - 31 January 2023 (12 months)
Add to pipelineImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Save Alert me Share this contractApplication Deadline
26 July 2021
Closed
Estimated Value
£469,741,550
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation → Release Date: 22 July 2022
Application Deadline: 26 July 2021
Contract Start Date: 1 February 2022
Contract End Date: 31 May 2024
Contract Duration: 2.3 years
Procurement ID (OCID): ocds-b5fd17-7ded634b-6b01-4af7-afda-87458f7f80be
Notice Reference: f872d76f-37e6-4b7e-b25e-c952ac8a42eb-556211
View Original Notice
Access the full notice on the official portal
Martindale Pharma
GB-CFS-215189
Rosemont Pharmaceuticals Limited GB-CFS-209840
Mercury Pharmaceuticals Limited GB-CFS-209849
Selective Supplies Ltd. GB-CFS-209835
Nexcape Pharmaceuticals Ltd. GB-CFS-215190
Consilient Health Ltd GB-CFS-215191
Fresenius Kabi Limited GB-CFS-181853
Glenmark Pharmaceuticals Europe Limited GB-CFS-186544
Laboratorio Reig Jofre SA GB-CFS-215192
Kent Pharma Ltd GB-CFS-186542
Bowmed Ibisqus Limited GB-CFS-215193
Panpharma UK Limited GB-CFS-215194
Kensington Pharma Ltd GB-CFS-215195
Healthcare Pharma Ltd GB-CFS-215196
Thornton and Ross Ltd GB-CFS-165045
Macleods Pharma UK Limited GB-CFS-215198
Wockhardt UK Limited GB-CFS-186547
Thea Pharmaceuticals Limited GB-CFS-215199
Dr Falk Pharma UK Ltd GB-CFS-215200
Desitin Pharma Ltd GB-CFS-215201
Stragen UK Ltd GB-CFS-215202
B. Braun Medical Limited GB-CFS-181856
Torrent Pharma UK Ltd GB-CFS-209882
Fontus Health Ltd GB-CFS-209865
Aspire Pharma Limited GB-CFS-215203
Teva UK Limited GB-CFS-165044
Amarox Limited GB-CFS-188189
AOP Orphan Ltd GB-CFS-215204
Pierre Fabre Ltd GB-CFS-215205
Macure Pharma ApS GB-CFS-215206
Arcadia Pharma Ltd T/A Arcadia Medical GB-CFS-215207
Zista Pharma Ltd GB-CFS-215209
Dr.Reddy's Laboratories (UK) Limited GB-CFS-165040
Aspen Pharmacare UK Limited GB-CFS-215210
Manx Healthcare Ltd GB-CFS-215211
Colonis Pharma Ltd GB-CFS-209855
Roche Products Ltd GB-CFS-215212
Waverley Pharma Europe Limited GB-CFS-215213
Profile Pharma Ltd GB-CFS-183756
Reckitt Benckiser GB-CFS-215214
Zentiva Pharma UK Ltd GB-CFS-165046
Baxter Healthcare Ltd GB-CFS-181854
Organon Pharmaceuticals UK Ltd GB-CFS-183742
Day Lewis Medical Ltd GB-CFS-215215
LogixX Pharma Ltd GB-CFS-215216
Lundbeck Limited GB-CFS-215217
Napp Pharmaceuticals Ltd GB-CFS-183734
Recordati Rare Diseases UK Ltd GB-CFS-215218
Morningside Pharmaeuticals GB-CFS-183759
Dexcel Pharma Ltd GB-CFS-186553
CST Pharma Limited GB-CFS-183757
Cipla (EU) Ltd GB-CFS-165039
Flexipharm Austrading Limited GB-CFS-215219
Relonchem Ltd GB-CFS-215220
Aguettant Ltd GB-CFS-209853
Torbay Pharmaceuticals GB-CFS-215222
RPH Pharmaceuticals AB GB-CFS-215223
Drugsrus Ltd GB-CFS-209844
Ferring Pharmaceuticals Ltd GB-CFS-183751
Milpharm Ltd/aurobinbdo GB-CFS-215224
Crescent Pharma Ltd GB-CFS-215225
Roma Pharmaceuticals Limited GB-CFS-215226
Kyowa Kirin Ltd GB-CFS-209871
Brown & Burk UK Ltd GB-CFS-215227
Seacross Pharmaceuticals Ltd GB-CFS-215228
Lupin Healthcare (UK) Limited GB-CFS-215229
Alliance Pharmaceuticals Limited GB-CFS-215230
Bristol Laboratories Limited GB-CFS-215231
Aristo Pharma Limited GB-CFS-215232
Alissa Healthcare Research Limited GB-CFS-215234
Altan Pharma Ltd GB-CFS-215235
Lucane Pharma GB-CFS-215236
Norgine Pharmaceuticals Limited GB-CFS-209838
Neon Healthcare Ltd GB-CFS-215237
Aventis Pharma ltd t/a Sanofi GB-CFS-183752
MIP Pharma GmbH GB-CFS-215238
Accord-UK Ltd GB-CFS-165037
Ascend Laboratories UK Ltd GB-CFS-215240
Rivopharm UK Ltd GB-CFS-215241
Strides Pharma Uk LTD GB-CFS-209875
Award value: £469,741,550 Award decision date: 30 November 2021 Award status: Active